Nexletol, Nustendi(bempedoic acid)
Nexletol, Nexlizet, Nilemdo, Nustendi (bempedoic acid) is a small molecule pharmaceutical. Bempedoic acid was first approved as Nexletol on 2020-02-21. It is used to treat atherosclerosis and hyperlipoproteinemia type II in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Nexletol
CombinationsNexlizet
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bempedoic acid
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NEXLETOL | Esperion Therapeutics | N-211616 RX | 2020-02-21 | 1 products, RLD, RS |
Bempedoic acid
+
Ezetimibe
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NEXLIZET | Esperion Therapeutics | N-211617 RX | 2020-02-26 | 1 products, RLD, RS |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BEMPEDOIC ACID, NEXLETOL, ESPERION THERAPS INC | |||
| 2025-02-21 | NCE | ||
BEMPEDOIC ACID / EZETIMIBE, NEXLIZET, ESPERION THERAPS INC | |||
| 2025-02-21 | NCE | ||
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AX: Other lipid modifying agents in atc
— C10AX15: Bempedoic acid
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA10: Bempedoic acid and ezetimibe
HCPCS
No data
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | — | — | — | — | — | 1 | — | 1 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | — | 1 | — | 1 |
| Dyslipidemias | D050171 | — | — | — | — | — | 1 | — | 1 |
| Familial combined hyperlipidemia | D006950 | EFO_0000492 | E78.49 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bempedoic acid |
| INN | bempedoic acid |
| Description | Bempedoic acid is an alpha,omega-dicarboxylic acid that is pentadecanedioic acid which is substituted by methyl groups groups at positions 2 and 14, and by a hydroxy group at position 8. It is a drug used for the treatment of high LDL cholesterol, which is sometimes referred to as 'bad cholesterol'. It has a role as an antilipemic drug, an EC 2.3.3.8 (ATP citrate synthase) inhibitor and a prodrug. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 738606-46-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545313 |
| ChEBI ID | — |
| PubChem CID | 10472693 |
| DrugBank | DB11936 |
| UNII ID | 1EJ6Z6Q368 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,159 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,017 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use